Francisca Ifesinachukwu, MD
Psychiatry · Austin, TXNPI 1558475335
Payments from drug & device makers
Across 1,743 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$5K
- Neuronetics, Inc.$5K
- AbbVie$3K
- Alkermes, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- plus $19K from 35 others
What the payments were for
- Food & beverage$34,36586%
- Education$3081%
- Other$5,30413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$5,304
- LYBALVI$2,247
- QELBREE$576
- INGREZZA$500
- Azstarys$496
- VRAYLAR$473
- REXULTI$471
- ABILIFY MAINTENA$451
- ARISTADA$430
- SPRAVATO$369
- Auvelity$362
- Jornay PM 20mg capsules (Bottle of 100)$232
- Dyanavel XR$230
- AUSTEDO$223
- ABILIFY ASIMTUFII$222
- Austedo XR$136
- Breyanzi$135
- COBENFY$122
- Fanapt$120
- QULIPTA$120
How this compares
$39,977 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $148,427 |
| Austedo XrDeutetrabenazine | 12 | $78,905 |
| RexultiBrexpiprazole | 34 | $57,631 |
| LybalviOlanzapine/Samidorphan Malate | 23 | $34,098 |
| VraylarCariprazine Hcl | 17 | $30,254 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $27,751 |
| BelsomraSuvorexant | 40 | $22,394 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $18,305 |
| FetzimaLevomilnacipran Hcl | 24 | $17,003 |
| HorizantGabapentin Enacarbil | 15 | $16,717 |
| Topiramate ErTopiramate | 31 | $14,418 |
| Lisdexamfetamine Dimesylate | 62 | $13,999 |
| UbrelvyUbrogepant | 14 | $13,985 |
| Adzenys Xr-OdtAmphetamine | 20 | $10,384 |
| QuviviqDaridorexant Hcl | 12 | $5,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,021 | $148,42717 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,135 | $78,90512 claims |
| AbbVieVraylar, Fetzima, Ubrelvy | $3,102 | $61,24255 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $5,397 | $57,63134 claims |
| Alkermes, Inc.Lybalvi | $3,083 | $34,09823 claims |
| MerckBelsomra | $50 | $22,39440 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $560 | $18,30536 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $316 | $16,71715 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $160 | $10,38420 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $399 | $5,87812 claims |
| Upsher-smith Laboratories LLCTopiramate | $93 | $61146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Austin
- David BrownAustin$15.8M
- Divyansu PatelAustin$2.8M
- Donald GarciaAustin$2.8M
- Arvinder Pal WaliaAustin$2.5M
- Charles SweetAustin$520K
- Charles NemeroffAustin$429K
- Scott BartleyDallas$42.7M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.